Oncoscience | A murine model for human early/immature T-cell precursor acute lymphoblastic leukemia (EITP ALL)
News, OncoscienceJanuary 23, 2023
“As anticipated, we found that the onset of leukemia was significantly accelerated in Idh2R140Q/NHD13 double transgenic mice […]”
BUFFALO, NY- January 23, 2023 – A new research perspective was published in Oncoscience (Volume 9) on October 24, 2022, entitled, “A murine model for human early/immature T-cell precursor acute lymphoblastic leukemia (EITP ALL).”
In this research perspective, researchers Vijay Negi and Peter D. Aplan from the National Institutes of Health’s National Cancer Institute discussed early/immature T cell precursor acute lymphoblastic leukemia (EITP ALL). EITP ALL represents a subset of human leukemias distinct from other T-ALL, and associated with poor prognosis. Clinical studies have identified chromosomal translocations involving the NUP98 gene and point mutations of IDH genes as recurrent mutations in patients with EITP-ALL.
“In a recent study using genetically engineered mice, we demonstrated that cooperation of an Idh2R140Q mutation with a NUP98-HOXD13 (NHD13) fusion gene resulted in EITP-ALL.”
Highlights of this double transgenic mouse model included the similarity of the immunophenotypic, mutational and gene expression landscape with human EITP-ALL. Additional studies showed that the Idh2R140Q/NHD13 EITP-ALL are sensitive to selective mutant IDH2 inhibitors in vitro, leading to the possibility that these mice can serve as a useful model for the study of EITP ALL development and therapy.
“We predict that the Idh2R140Q/NHD13 mouse model will serve as an excellent tool to study EITP biology and identify therapies for patients with EITP leukemia.”
Correspondence to: Peter D. Aplan – Email: [email protected]
Keywords: early thymocyte precursor (ETP), leukemia, IDH2, NUP98, NHD13
Oncoscience Videos: YouTube
Oncoscience is a peer-reviewed, open-access, traditional journal covering the rapidly growing field of cancer research, especially emergent topics not currently covered by other journals. This journal has a special mission: Freeing oncology from publication cost. It is free for the readers and the authors.
To learn more about Oncoscience, visit Oncoscience.us and connect with us on social media:
- Twitter – https://twitter.com/OncoscienceJrnl
- Facebook – https://www.facebook.com/Oncoscience
- YouTube – https://www.youtube.com/@OncoscienceJournal
- LinkedIn – https://www.linkedin.com/company/oncoscience/
For media inquiries, please contact [email protected]ctjournals.com.